Blinatumomab Active in Ph+ B-Precursor Acute Lymphoblastic Leukemia
Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor–relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia.
Global Inequities in Childhood Leukemia Survival Still Persist
Global inequities in childhood leukemia survival have narrowed in recent years but still persist, according to data from CONCORD-2.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML
Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation.
Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL
Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.
TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension.
FDA Warns of Rare Cancer Linked to Breast Implants
The FDA has recently released a statement identifying a new rare T-cell lymphoma caused by breast implant surgery.
Hodgkin Lymphoma Survivors at High Risk for Second Cancers
Patients who have survived Hodgkin lymphoma were at more than double the risk for diagnosis with a second cancer, according to the results of a recent study.
By clicking Accept, you agree to become a member of the UBM Medica Community.